Horien Biochemical Technology Co (ROCO:7814) ROE %: 7.11% (As of Dec. 2025) — 199% Above Median


ROCO:7814 Horien Biochemical Technology Co Ltd ROCO:7814
21 GF Score
Price NT$37.80
! 5 Warning Signs
View Full Analysis

What is Horien Biochemical Technology Co ROE %?

Horien Biochemical Technology Co ROCO:7814 +2.16% 21 ROE % is 7.11% as of Dec. 2025, which is 199% above its 10-year median of 2.38. GuruFocus rates ROCO:7814 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review. Among 1,250 Biotechnology companies, Horien Biochemical Technology Co ranks better than 81.12% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Horien Biochemical Technology Co's annualized net income for the quarter that ended in Dec. 2025 was NT$20.73 Mil. Horien Biochemical Technology Co's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was NT$291.52 Mil. Therefore, Horien Biochemical Technology Co's annualized ROE % for the quarter that ended in Dec. 2025 was 7.11%.

The historical rank and industry rank for Horien Biochemical Technology Co's ROE % or its related term are showing as below:

ROCO:7814' s ROE % Range Over the Past 10 Years
Min: -1.69   Med: 2.38   Max: 8.75
Current: 2.75

During the past 4 years, Horien Biochemical Technology Co's highest ROE % was 8.75%. The lowest was -1.69%. And the median was 2.38%.

ROCO:7814's ROE % is ranked better than
81.12% of 1250 companies
in the Biotechnology industry
Industry Median: -38.26 vs ROCO:7814: 2.75

Horien Biochemical Technology Co  (ROCO:7814) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=20.732/291.5155
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(20.732 / 110.092)*(110.092 / 318.795)*(318.795 / 291.5155)
=Net Margin %*Asset Turnover*Equity Multiplier
=18.83 %*0.3453*1.0936
=ROA %*Equity Multiplier
=6.5 %*1.0936
=7.11 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=20.732/291.5155
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (20.732 / 20.732) * (20.732 / 16.712) * (16.712 / 110.092) * (110.092 / 318.795) * (318.795 / 291.5155)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.2405 * 15.18 % * 0.3453 * 1.0936
=7.11 %

Note: The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Horien Biochemical Technology Co ROE % Related Terms


Horien Biochemical Technology Co ROE % Historical Data

* Premium members only.

The historical data trend for Horien Biochemical Technology Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Horien Biochemical Technology Co ROE % Chart

Horien Biochemical Technology Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE %
1.56 8.75 3.20 -1.69

Horien Biochemical Technology Co Quarterly Data
Dec22 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
ROE % Get a 7-Day Free Trial 26.31 9.90 0.00 3.97 7.11

ROCO:7814 vs VRTX, REGN, ALNY: ROE % Comparison

For the Biotechnology subindustry, Horien Biochemical Technology Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Horien Biochemical Technology Co ROE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Horien Biochemical Technology Co's ROE % distribution charts can be found below:

* The bar in red indicates where Horien Biochemical Technology Co's ROE % falls into.


ROCO:7814
21GF Score
Horien Biochemical Technology Co Ltd ROCO:7814
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Horien Biochemical Technology Co ROE % Calculation

Horien Biochemical Technology Co's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-5.004/( (299.111+294.107)/ 2 )
=-5.004/296.609
=-1.69 %

Horien Biochemical Technology Co's annualized ROE % for the quarter that ended in Dec. 2025 is calculated as

ROE %=Net Income (Q: Dec. 2025 )/( (Total Stockholders Equity (Q: Sep. 2025 )+Total Stockholders Equity (Q: Dec. 2025 ))/ count )
=20.732/( (288.924+294.107)/ 2 )
=20.732/291.5155
=7.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2025) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 7.11% mean?
Horien Biochemical Technology Co (ROCO:7814) has a ROE % of 7.11% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Horien Biochemical Technology Co and its competitors. This is 199% above median its historical median of 2.38. According to the industry distribution chart, Horien Biochemical Technology Co ranks #236 out of 1250 companies in the Biotechnology industry, placing it in the top 18.9%.
Is Horien Biochemical Technology Co's ROE % too high?
Horien Biochemical Technology Co's current ROE % of 7.11% is 199% above median its 10-year median of 2.38. Based on the distribution chart, Horien Biochemical Technology Co ranks #236 out of 1250 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Horien Biochemical Technology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Horien Biochemical Technology Co's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Horien Biochemical Technology Co ranks #236 out of 1250 companies for ROE %. This places Horien Biochemical Technology Co in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Horien Biochemical Technology Co and its competitors. Horien Biochemical Technology Co's current ROE % is 7.11%, which is 199% above median its own 10-year median of 2.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Horien Biochemical Technology Co stock overvalued right now?
Horien Biochemical Technology Co (ROCO:7814) has a current ROE % of 7.11%. The current ROE % is 7.11%, which is 199% above median its 10-year median of 2.38. Horien Biochemical Technology Co's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Horien Biochemical Technology Co (ROCO:7814), the current ROE % is 7.11% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Horien Biochemical Technology Co Business Description

Address Gongyecyu 38th Road, 7F-5 & 6, NO. 210, Situn District, Siehe Village, Taichung, TWN, 40768
Horien Biochemical Technology Co Ltd is engaged in the research and development of cosmetic raw materials and medical devices and facilities. The products of the company include Gen-Nusis, skin repairment ingredients, PeptioMax, the latest cosmetic raw material, Lifkin, and other substitutes used in dentistry and general surgery.
21GF Score

Get the complete analysis for ROCO:7814

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$37.80
Price